Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

A, Viardot; ME, Goebeler; G, Hess; S, Neumann; M, Pfreundschuh; N, Adrian; F, Zettl; M, Libicher; C, Sayehli; J, Stieglmaier; A, Zhang; D, Nagorsen; RC, Bargou

doi:10.1182/blood-2015-06-651380

Public

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

Published in Blood • Jan 11, 2016

Authors:

Viardot A

Goebeler ME

Hess G

Abstract

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells to CD19-positive B cells. This phase 2 study evaluated stepwise (9-28-112 μg/d wi...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!